These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 35337094)

  • 1. Continuous Versus Intermittent Linezolid Infusion for Critically Ill Patients with Hospital-Acquired and Ventilator-Associated Pneumonia: Efficacy and Safety Challenges.
    Abou Warda AE; Sarhan RM; Al-Fishawy HS; Moharram AN; Salem HF
    Pharmaceuticals (Basel); 2022 Feb; 15(3):. PubMed ID: 35337094
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alveolar diffusion and pharmacokinetics of linezolid administered in continuous infusion to critically ill patients with ventilator-associated pneumonia.
    Boselli E; Breilh D; Caillault-Sergent A; Djabarouti S; Guillaume C; Xuereb F; Bouvet L; Rimmelé T; Saux MC; Allaouchiche B
    J Antimicrob Chemother; 2012 May; 67(5):1207-10. PubMed ID: 22351682
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Linezolid pharmacokinetic/pharmacodynamic profile in critically ill septic patients: intermittent versus continuous infusion.
    Adembri C; Fallani S; Cassetta MI; Arrigucci S; Ottaviano A; Pecile P; Mazzei T; De Gaudio R; Novelli A
    Int J Antimicrob Agents; 2008 Feb; 31(2):122-9. PubMed ID: 18055183
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Applying pharmacokinetic/pharmacodynamic measurements for linezolid in critically ill patients: optimizing efficacy and reducing resistance occurrence.
    El-Gaml RM; El-Khodary NM; Abozahra RR; El-Tayar AA; El-Masry SM
    Eur J Clin Pharmacol; 2022 Aug; 78(8):1301-1310. PubMed ID: 35610318
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Linezolid plasma and intrapulmonary concentrations in critically ill obese patients with ventilator-associated pneumonia: intermittent vs continuous administration.
    De Pascale G; Fortuna S; Tumbarello M; Cutuli SL; Vallecoccia M; Spanu T; Bello G; Montini L; Pennisi MA; Navarra P; Antonelli M
    Intensive Care Med; 2015 Jan; 41(1):103-10. PubMed ID: 25413377
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of clinical cure rates in adults with ventilator-associated pneumonia treated with intravenous ceftazidime administered by continuous or intermittent infusion: a retrospective, nonrandomized, open-label, historical chart review.
    Lorente L; Jiménez A; Palmero S; Jiménez JJ; Iribarren JL; Santana M; Martín MM; Mora ML
    Clin Ther; 2007 Nov; 29(11):2433-9. PubMed ID: 18158083
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and microbiological efficacy of continuous versus intermittent application of meropenem in critically ill patients: a randomized open-label controlled trial.
    Chytra I; Stepan M; Benes J; Pelnar P; Zidkova A; Bergerova T; Pradl R; Kasal E
    Crit Care; 2012 Jun; 16(3):R113. PubMed ID: 22742765
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Continuous infusion versus intermittent administration of ceftazidime in critically ill patients with suspected gram-negative infections.
    Benko AS; Cappelletty DM; Kruse JA; Rybak MJ
    Antimicrob Agents Chemother; 1996 Mar; 40(3):691-5. PubMed ID: 8851594
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Beta-Lactam Infusion in Severe Sepsis (BLISS): a prospective, two-centre, open-labelled randomised controlled trial of continuous versus intermittent beta-lactam infusion in critically ill patients with severe sepsis.
    Abdul-Aziz MH; Sulaiman H; Mat-Nor MB; Rai V; Wong KK; Hasan MS; Abd Rahman AN; Jamal JA; Wallis SC; Lipman J; Staatz CE; Roberts JA
    Intensive Care Med; 2016 Oct; 42(10):1535-1545. PubMed ID: 26754759
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and intrapulmonary concentrations of linezolid administered to critically ill patients with ventilator-associated pneumonia.
    Boselli E; Breilh D; Rimmelé T; Djabarouti S; Toutain J; Chassard D; Saux MC; Allaouchiche B
    Crit Care Med; 2005 Jul; 33(7):1529-33. PubMed ID: 16003058
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Linezolid versus teicoplanin in the treatment of Gram-positive infections in the critically ill: a randomized, double-blind, multicentre study.
    Cepeda JA; Whitehouse T; Cooper B; Hails J; Jones K; Kwaku F; Taylor L; Hayman S; Shaw S; Kibbler C; Shulman R; Singer M; Wilson AP
    J Antimicrob Chemother; 2004 Feb; 53(2):345-55. PubMed ID: 14711840
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Linezolid more efficacious than vancomycin to eradicate infecting organism in critically ill patients with Gram-positive infections.
    Sirvent JM; Piñeiro L; de la Torre M; Motjé M; de Batlle J; Bonet A
    Rev Esp Quimioter; 2010 Mar; 23(1):27-35. PubMed ID: 20232021
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Continuous Piperacillin-Tazobactam Infusion Improves Clinical Outcomes in Critically Ill Patients with Sepsis: A Retrospective, Single-Centre Study.
    Hyun DG; Seo J; Lee SY; Ahn JH; Hong SB; Lim CM; Koh Y; Huh JW
    Antibiotics (Basel); 2022 Oct; 11(11):. PubMed ID: 36358163
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is continuous infusion ceftriaxone better than once-a-day dosing in intensive care? A randomized controlled pilot study.
    Roberts JA; Boots R; Rickard CM; Thomas P; Quinn J; Roberts DM; Richards B; Lipman J
    J Antimicrob Chemother; 2007 Feb; 59(2):285-91. PubMed ID: 17135183
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of tedizolid for the treatment of ventilated gram-positive hospital-acquired or ventilator-associated bacterial pneumonia in Japanese patients: Results from a subgroup analysis of a phase 3, randomized, double-blind study comparing tedizolid and linezolid.
    Mikamo H; Nagashima M; Kusachi S; Fujimi S; Oshima N; De Anda C; Takase A
    J Infect Chemother; 2022 Sep; 28(9):1235-1241. PubMed ID: 35718656
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo efficacy of continuous infusion versus intermittent dosing of linezolid compared to vancomycin in a methicillin-resistant Staphylococcus aureus rabbit endocarditis model.
    Jacqueline C; Batard E; Perez L; Boutoille D; Hamel A; Caillon J; Kergueris MF; Potel G; Bugnon D
    Antimicrob Agents Chemother; 2002 Dec; 46(12):3706-11. PubMed ID: 12435665
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial.
    Wunderink RG; Matsunaga Y; Ariyasu M; Clevenbergh P; Echols R; Kaye KS; Kollef M; Menon A; Pogue JM; Shorr AF; Timsit JF; Zeitlinger M; Nagata TD
    Lancet Infect Dis; 2021 Feb; 21(2):213-225. PubMed ID: 33058798
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of ceftazidime by continuous infusion versus intermittent infusion for nosocomial pneumonia.
    McNabb JJ; Nightingale CH; Quintiliani R; Nicolau DP
    Pharmacotherapy; 2001 May; 21(5):549-55. PubMed ID: 11349744
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Meropenem by continuous versus intermittent infusion in ventilator-associated pneumonia due to gram-negative bacilli.
    Lorente L; Lorenzo L; Martín MM; Jiménez A; Mora ML
    Ann Pharmacother; 2006 Feb; 40(2):219-23. PubMed ID: 16449546
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.